Research progess in effect of novel coronavirus on cardiovascular system_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LI Lei ¹ , PENG Yixue ¹ , ZHANG Jie ¹ , ZHUO Lijia ¹ , ZHAO Xia ¹ , ZHANG Longhao ² , ZHU Peijia ³ ,  ZENG Guojun ⁴

1. Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
2. Double First-class Construction Office, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
4. Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

ZENG Guojun, Email: benesun@qq.com

Keywords：

SARS-CoV-2; COVID-19; cardiovascular system; review

DOI：

10.7507/1007-4848.202101012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In addition to the typical respiratory symptoms, COVID-19 patients present with clinical manifestations of cardiovascular system damage, and they are at higher risk of intensive care or mortality. The mechanism of COVID-19's impact on the cardiovascular system is still unclear, therefore we need to pay close attention to it. Based on the existing research, this paper focused on the concurrent characteristics of the cardiovascular system diseases, summarized the possible mechanisms of cardiovascular system damage, including the coronavirus invaders directly into cardiomyocytes and its conduction system, with complications or accompanying conditions such as cytokine storm, imbalance of oxygen supply and demand, drug influence, stress and other damage to cardiovascular system. Meanwhile, current clinical manifestations and treatment methods of COVID-19 were summarized.

Citation： LI Lei, PENG Yixue, ZHANG Jie, ZHUO Lijia, ZHAO Xia, ZHANG Longhao, ZHU Peijia, ZENG Guojun. Research progess in effect of novel coronavirus on cardiovascular system. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(1): 106-113. doi: 10.7507/1007-4848.202101012 Copy

1.	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2.	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet, 2020, 395(10224): 565-574.
3.	刘欣, 丛晓东, 李平. 探讨新型冠状病毒对心血管系统的影响. 山东中医药大学学报, 2020 , 44(6): 462-546.
4.	World Health Organization. SARS-CoV-2 variant—United Kingdom of Great Britain and Northern Ireland. 2020-12-21.
5.	SARS-CoV-2 variants. World Health Organization. 2020-12-31.
6.	Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13): 1239-1242.
7.	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062.
8.	戴海龙, 冯晓岚, 周旭, 等. 新型冠状病毒肺炎对心血管的影响. 心肺血管病杂志, 2021, 39(6): 635-647, 641.
9.	张梅, 李闯. 新型冠状病毒肺炎与心血管疾病. 武警医学, 2020, 31(2): 93-96.
10.	倪国华, 李昆, 袁琼. 新型冠状病毒肺炎合并心血管疾病患者使用抗病毒药物的药学监护. 实用医学杂志, 2020, 36(6): 3169-3173.
11.	Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020, 109(5): 531-538.
12.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
13.	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223): 507-513.
14.	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069.
15.	Li D, Chen Y, Liu H, et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: Insights from ERS-COVID-19 study. Signal Transduct Target Ther, 2020, 5(1): 62.
16.	国家卫生健康委办公厅国家中医药管理局办公室. 关于印发新型冠状病毒肺炎诊疗方案(试行第八版)的通知. 江苏中医药, 2020, 52(9): 封2, 前插1-前插4.
17.	Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest, 2009, 39(7): 618-625.
18.	李发久, 朱紫阳, 陈实, 等. 新型冠状病毒肺炎相关心肌损伤的临床观察. 第二军医大学学报, 2020, 42(5): 698-703.
19.	姜淑芳, 袁本敏, 韩志武. 新型冠状病毒感染与心血管疾病. 青岛大学学报(医学版), 2020, 57(1): 156-158.
20.	Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7): 811-818.
21.	Guo J, Huang Z, Lin L, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc, 2020, 9(7): e016219.
22.	Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol, 2020, 75(18): 2352-2371.
23.	Prasad A, Panhwar S, Hendel RC, et al. COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J, 2020, 226: 174-187.
24.	Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation, 2020, 141(20): 1648-1655.
25.	Nguyen JL, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol, 2016, 1(3): 274-281.
26.	Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J, 2020, 41(19): 1798-1800.
27.	张凤艳, 乔英, 张辉. 新型冠状病毒肺炎的临床及CT表现研究进展. 山西医科大学学报, 2020, 56(5): 466-469.
28.	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
29.	Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res, 2020, 116(10): 1666-1687.
30.	丛超, 郭义山, 王东. 病毒性心肌炎发病机制的研究进展. 医学综述, 2020, 41(2): 144-147.
31.	Wang M, Zhang W, Zhou Y, et al. Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med, 2014, 7(6): 1721-1727.
32.	Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483): 1260-1263.
33.	徐敏. 地震灾难对军队医护人员应急救援时心理健康的影响. 中国实用护理杂志, 2018, 34(17): 1314-1316.
34.	Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology, 2020, 160(3): 261-268.
35.	Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol, 2020, 92(11): 2283-2285.
36.	易春峰, 张帆, 杨力, 等. 新型冠状病毒肺炎患者心肌损伤与炎症相关性分析. 实用医学杂志, 2020, 36(23): 3174-3178.
37.	Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm, 2020, 17(9): 1463-1471.
38.	张竞文, 胡欣, 金鹏飞. 新型冠状病毒引起的细胞因子风暴及其药物治疗. 中国药学杂志, 2020, 55(5): 333-336.
39.	Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol, 2012, 86(11): 6055-6066.
40.	Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virusinduced viral pneumonia in the rhesus macaque. Virol, 2012, 86(11): 6055-6066.
41.	吴彪, 王春友. SIRS患者炎症因子变化与病情相关性的研究. 中国现代普通外科进展, 2011, 14(6): 501-502.
42.	肖颖彬. 加强新冠肺炎对心血管系统损害的研究. 第三军医大学学报, 2021, 43(3): 183-187.
43.	Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, 17(5): 259-260.
44.	Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID-19 disease. Nat Commun, 2020, 11(1): 5859.
45.	Li D, Chen Y, Jia Y, et al. SARS-CoV-2-induced immune dysregulation and myocardial injury risk in China: Insights from the ERS-COVID-19 study. Circ Res, 2020, 127(3): 397-399.
46.	Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 2021, 184(3): 775-791.
47.	Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth, 2014, 58(5): 515-523.
48.	Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020, 182(1): 59-72.
49.	Zheng Y, Zhang Y, Chi H, et al. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: A retrospective study. Clin Chem Lab Med, 2020, 58(7): 1106-1115.
50.	Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta, 2020, 506: 145-148.
51.	王曦, 安松涛, 李文博, 等. 新型冠状病毒对循环系统影响的研究进展. 中华全科医学, 2021, 19(2): 293-297.
52.	Mahenthiran AK, Mahenthiran AK, Mahenthiran J. Cardiovascular system and COVID-19: Manifestations and therapeutics. Rev Cardiovasc Med, 2020, 21(3): 399-409.
53.	王从容, 徐霞, 陈雅慧. 抗病毒药物在新型冠状病毒肺炎治疗中的合理使用与药学监护. 中国医院药学杂志, 2020, 40(10): 1693-2286.
54.	刘海淑. 干扰素在心血管方面的研究及临床应用. 实用心脑肺血管病杂志, 2005, 13(2): 116-118.
55.	付琦, 马秀云, 徐艳丽. 利巴韦林治疗SARS患者致心率减慢的病例对照研究. 药物不良反应杂志, 2004, 6(3): 154-156.
56.	庞文渊, 王乔宇, 赵志刚. 阿比多尔治疗病毒性疾病的应用及评估. 中国药物警戒, 2020, 17(6): 321-325, 337.
57.	郭栋, 郭万刚, 刘鹏云, 等. 新型冠状病毒感染的心脏表现. 心脏杂志, 2020, 32(1): 75-77.
58.	张劲农. 武汉协和医院处置2019新型冠状病毒感染策略及说明. URL: https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q. Accessed on 2020-01-23.
59.	新冠肺炎诊疗方案治疗药物信息汇编 (第1版). 中南药学, 2020, 18(3): 345-358.
60.	Kunal S, Gupta K, Sharma SM, et al. Cardiovascular system and COVID-19: Perspectives from a developing country. Monaldi Arch Chest Dis, 2020, 90(2).
61.	Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41(2): 145-151.
62.	Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly, 2020, 2(8): 113-22.
63.	Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis, 2020, 20(6): 630-631.
64.	Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep, 2020, 69(24): 759-765.
65.	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
66.	Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N Engl J Med, 2020, 382(25): 2431-2440.
67.	Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens, 2020, 38(5): 781-782.
68.	Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med, 2020, 382(17): 1653-1659.
69.	Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med, 2020, 382(25): e102.
70.	Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med, 2020, 382(25): 2441-2448.
71.	张晨阳, 邵冬雪, 郑曦, 等. ACE2与新型冠状病毒肺炎的心肾损伤. 实用药物与临床, 2020, 23(10): 944-951.
72.	卜军, 陈茂, 程晓曙, 等. 新型冠状病毒肺炎防控形势下急性心肌梗死诊治流程和路径的中国专家共识(第1版). 南方医科大学学报, 2020, 40(2): 147-151.
73.	Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64(24): e139-e228.
74.	Key questions on COVID-19 and cardiovascular disease. Am Coll Cardiol, 2020-4-30.
75.	李美瑜, 吕明芳, 李翠芝, 等. 不同临床分型新型冠状病毒肺炎患者的心脏表现特征. 广东医学, 2020, 41(8): 797-800.
76.	蔡金原. 血管紧张素转化酶2在新型冠状病毒肺炎中的作用研究进展. 医学研究生学报, 2021, 34(1): 107-112.
77.	Cox CE. Rivaroxaban may yet protect after a hospital dtay: MARINER. TCTMD—Cardiovascular Research Foundation. 2020-6-25.
78.	Wang J, Xu H, Yang X, et al. Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis, 2017, 21(1): 12-18.
79.	Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA, 2015, 313(3): 264-274.
80.	Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet, 2020, 395(10239): 1771-1778.

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet, 2020, 395(10224): 565-574.
3. 刘欣, 丛晓东, 李平. 探讨新型冠状病毒对心血管系统的影响. 山东中医药大学学报, 2020 , 44(6): 462-546.
4. World Health Organization. SARS-CoV-2 variant—United Kingdom of Great Britain and Northern Ireland. 2020-12-21.
5. SARS-CoV-2 variants. World Health Organization. 2020-12-31.
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13): 1239-1242.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062.
8. 戴海龙, 冯晓岚, 周旭, 等. 新型冠状病毒肺炎对心血管的影响. 心肺血管病杂志, 2021, 39(6): 635-647, 641.
9. 张梅, 李闯. 新型冠状病毒肺炎与心血管疾病. 武警医学, 2020, 31(2): 93-96.
10. 倪国华, 李昆, 袁琼. 新型冠状病毒肺炎合并心血管疾病患者使用抗病毒药物的药学监护. 实用医学杂志, 2020, 36(6): 3169-3173.
11. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020, 109(5): 531-538.
12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
13. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223): 507-513.
14. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069.
15. Li D, Chen Y, Liu H, et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: Insights from ERS-COVID-19 study. Signal Transduct Target Ther, 2020, 5(1): 62.
16. 国家卫生健康委办公厅国家中医药管理局办公室. 关于印发新型冠状病毒肺炎诊疗方案(试行第八版)的通知. 江苏中医药, 2020, 52(9): 封2, 前插1-前插4.
17. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest, 2009, 39(7): 618-625.
18. 李发久, 朱紫阳, 陈实, 等. 新型冠状病毒肺炎相关心肌损伤的临床观察. 第二军医大学学报, 2020, 42(5): 698-703.
19. 姜淑芳, 袁本敏, 韩志武. 新型冠状病毒感染与心血管疾病. 青岛大学学报(医学版), 2020, 57(1): 156-158.
20. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7): 811-818.
21. Guo J, Huang Z, Lin L, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc, 2020, 9(7): e016219.
22. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol, 2020, 75(18): 2352-2371.
23. Prasad A, Panhwar S, Hendel RC, et al. COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J, 2020, 226: 174-187.
24. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation, 2020, 141(20): 1648-1655.
25. Nguyen JL, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol, 2016, 1(3): 274-281.
26. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J, 2020, 41(19): 1798-1800.
27. 张凤艳, 乔英, 张辉. 新型冠状病毒肺炎的临床及CT表现研究进展. 山西医科大学学报, 2020, 56(5): 466-469.
28. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
29. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res, 2020, 116(10): 1666-1687.
30. 丛超, 郭义山, 王东. 病毒性心肌炎发病机制的研究进展. 医学综述, 2020, 41(2): 144-147.
31. Wang M, Zhang W, Zhou Y, et al. Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med, 2014, 7(6): 1721-1727.
32. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483): 1260-1263.
33. 徐敏. 地震灾难对军队医护人员应急救援时心理健康的影响. 中国实用护理杂志, 2018, 34(17): 1314-1316.
34. Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology, 2020, 160(3): 261-268.
35. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol, 2020, 92(11): 2283-2285.
36. 易春峰, 张帆, 杨力, 等. 新型冠状病毒肺炎患者心肌损伤与炎症相关性分析. 实用医学杂志, 2020, 36(23): 3174-3178.
37. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm, 2020, 17(9): 1463-1471.
38. 张竞文, 胡欣, 金鹏飞. 新型冠状病毒引起的细胞因子风暴及其药物治疗. 中国药学杂志, 2020, 55(5): 333-336.
39. Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol, 2012, 86(11): 6055-6066.
40. Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virusinduced viral pneumonia in the rhesus macaque. Virol, 2012, 86(11): 6055-6066.
41. 吴彪, 王春友. SIRS患者炎症因子变化与病情相关性的研究. 中国现代普通外科进展, 2011, 14(6): 501-502.
42. 肖颖彬. 加强新冠肺炎对心血管系统损害的研究. 第三军医大学学报, 2021, 43(3): 183-187.
43. Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, 17(5): 259-260.
44. Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID-19 disease. Nat Commun, 2020, 11(1): 5859.
45. Li D, Chen Y, Jia Y, et al. SARS-CoV-2-induced immune dysregulation and myocardial injury risk in China: Insights from the ERS-COVID-19 study. Circ Res, 2020, 127(3): 397-399.
46. Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 2021, 184(3): 775-791.
47. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth, 2014, 58(5): 515-523.
48. Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020, 182(1): 59-72.
49. Zheng Y, Zhang Y, Chi H, et al. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: A retrospective study. Clin Chem Lab Med, 2020, 58(7): 1106-1115.
50. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta, 2020, 506: 145-148.
51. 王曦, 安松涛, 李文博, 等. 新型冠状病毒对循环系统影响的研究进展. 中华全科医学, 2021, 19(2): 293-297.
52. Mahenthiran AK, Mahenthiran AK, Mahenthiran J. Cardiovascular system and COVID-19: Manifestations and therapeutics. Rev Cardiovasc Med, 2020, 21(3): 399-409.
53. 王从容, 徐霞, 陈雅慧. 抗病毒药物在新型冠状病毒肺炎治疗中的合理使用与药学监护. 中国医院药学杂志, 2020, 40(10): 1693-2286.
54. 刘海淑. 干扰素在心血管方面的研究及临床应用. 实用心脑肺血管病杂志, 2005, 13(2): 116-118.
55. 付琦, 马秀云, 徐艳丽. 利巴韦林治疗SARS患者致心率减慢的病例对照研究. 药物不良反应杂志, 2004, 6(3): 154-156.
56. 庞文渊, 王乔宇, 赵志刚. 阿比多尔治疗病毒性疾病的应用及评估. 中国药物警戒, 2020, 17(6): 321-325, 337.
57. 郭栋, 郭万刚, 刘鹏云, 等. 新型冠状病毒感染的心脏表现. 心脏杂志, 2020, 32(1): 75-77.
58. 张劲农. 武汉协和医院处置2019新型冠状病毒感染策略及说明. URL: https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q. Accessed on 2020-01-23.
59. 新冠肺炎诊疗方案治疗药物信息汇编 (第1版). 中南药学, 2020, 18(3): 345-358.
60. Kunal S, Gupta K, Sharma SM, et al. Cardiovascular system and COVID-19: Perspectives from a developing country. Monaldi Arch Chest Dis, 2020, 90(2).
61. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41(2): 145-151.
62. Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly, 2020, 2(8): 113-22.
63. Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis, 2020, 20(6): 630-631.
64. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep, 2020, 69(24): 759-765.
65. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
66. Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N Engl J Med, 2020, 382(25): 2431-2440.
67. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens, 2020, 38(5): 781-782.
68. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med, 2020, 382(17): 1653-1659.
69. Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med, 2020, 382(25): e102.
70. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med, 2020, 382(25): 2441-2448.
71. 张晨阳, 邵冬雪, 郑曦, 等. ACE2与新型冠状病毒肺炎的心肾损伤. 实用药物与临床, 2020, 23(10): 944-951.
72. 卜军, 陈茂, 程晓曙, 等. 新型冠状病毒肺炎防控形势下急性心肌梗死诊治流程和路径的中国专家共识(第1版). 南方医科大学学报, 2020, 40(2): 147-151.
73. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64(24): e139-e228.
74. Key questions on COVID-19 and cardiovascular disease. Am Coll Cardiol, 2020-4-30.
75. 李美瑜, 吕明芳, 李翠芝, 等. 不同临床分型新型冠状病毒肺炎患者的心脏表现特征. 广东医学, 2020, 41(8): 797-800.
76. 蔡金原. 血管紧张素转化酶2在新型冠状病毒肺炎中的作用研究进展. 医学研究生学报, 2021, 34(1): 107-112.
77. Cox CE. Rivaroxaban may yet protect after a hospital dtay: MARINER. TCTMD—Cardiovascular Research Foundation. 2020-6-25.
78. Wang J, Xu H, Yang X, et al. Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis, 2017, 21(1): 12-18.
79. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA, 2015, 313(3): 264-274.
80. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet, 2020, 395(10239): 1771-1778.

Previous Article
Progress in diagnosis and treatment of brain metastasis from colorectal cancer
Next Article
Research status of relationship between hepatitis B virus genotypes and hepatocarcinogenesis

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progess in effect of novel coronavirus on cardiovascular system

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content